Developing first-in-class therapeutics based on cutting-edge science:

ExomeresTM by Exopharm.

 

Therapeutic ExomeresTM

from Stem Cells

Exomeres are biological nanoparticles naturally secreted by stem cells. They are produced using Exopharm’s proprietary LEAP process, which delivers a unique blend of exosomes / vesicles with high-yield.


Exomeres are a cell-free super-drug with the potential to treat a range of conditions such as osteoarthritis, eye disease and fibrosis as a regenerative medicine.


Exomeres carry a rich molecular cargo of nucleic acids, lipids and proteins and are taken up by cells inside the body.


Harnessing natural mechanisms, Exomeres transfer information, energy and cell building materials between cells that promote tissue repair, healing and regeneration

Advancing knowledge in stem-cell therapy is demonstrating that positive medical outcomes can be achieved even without using the therapeutic cells themselves. Instead, the essential therapeutic components are the cell-secreted extracellular vesicles (EVs), including exosomes.


It has become apparent that these EVs alone are sufficient to deliver beneficial effects in models of disease – by efficient delivery of the information, machinery and energy to drive repair programs in damaged tissues. While delivering the therapeutic benefits, Exomeres offer a range of advantages over the use of cells for therapy. Being cell-free, they are easy to transport and deliver to patients around the world. Exomeres also cause less concern over their safety as they are not living cells: they have much more pharmaceutical properties and will not remain in the body for extended periods.


Exomeres – a completely new class of biological therapeutic.

Exopharm is investing in the pharma-grade manufacturing process and preclinical development of Exomeres to enable first clinical trials for the treatment of joint conditions, eye disease and fibrosis.

News

Special delivery: Exosomes – the natural nano-bio delivery drones

In the not too distant future, click ‘buy’ on an internet shopping site and an autonomous drone will be dispatched to carry your new goods directly to your doorstop. For now, regular drone home-delivery is still science fiction. But inside the body, targeted autonomous delivery of packages is already a reality. Cells use nanoscale spheres called exosomes to mail out packages of proteins, RNA and other biomolecules. These 100-nanometre-sized spheres (visible only through electron microscopy) travel freely around the body, their tiny proportions ensuring they can penetrate deep into the tissues. Exosomes are secreted (sent off) by one cell type and are often tagged for uptake by...
Read More

Extending the healthspan – living long and staying healthy.

Exosomes are one of the most promising potential treatments for staving off age- related disease, keeping us fit and healthy throughout our natural lives. Modern medicine has been phenomenally successful at extending human lifespan, particularly for individuals born in the developed world. A baby born in the US today has a life expectancy of almost 79 years. In Australia it is 82 years, a full decade longer than a baby born in 1975. And this upward trend in life expectancy shows no sign of slowing. But while we are living for more years, the extra years we are getting are not necessarily good ones. The number of years we can expect to remain fit and healthy has not extended at the...
Read More

Investor wonder-land – wonderful companies and where they come from

Investor wonder-land – wonderful companies and where they come from By Dr Ian Dixon Shareholders and investors are always on the lookout for a listed company that might deliver exceptional returns – and by that I mean more than 5 times your money over 2 or 3 years. Here is a guide that you might find useful. Firstly, you might be doubtful that this author has any idea whatsoever on this topic. Fortunately, I have indeed been at the heart of a few companies that fit this criterion – Noxopharm (I am a founder – director of NOX) has delivered some fortunate investors a 2,000% return over a bit more than 2 years and Cynata Therapeutics Ltd (I am a co-founder of...
Read More

Our Team.

Dr. Ian Dixon

CEO

linkedin

Dr. Gregor Lichtfuss

COO

twitter linkedin

Dr. Jim Palmer

Drug Development

linkedin

Ellie Mohammadi

Communication and Program Director

linkedin

Melbourne - Australia